82225SightPlus DiagnosticClosedCR&D BilateralInnovate UKGlobally, some 217 million people are affected by sight impediments. These conditions have a negative impact on su?erers' well-being in terms of social inclusion, independence, ability to carry out activities of daily living, quality of life, and health and expose groups suffering them that include the elderly to even more vulnerability in their daily lives. These diseases require on-going assessment for optimal management, burdening patients, and their families whilst proving to be costly for health care systems. Challenges that have been compounded and exposed further during the Covid-19 pandemic which resulted in patients not being able to access the care needed as a result of the need for them to remain self-isolated whilst direct access to Doctors became limited. Building on the success of our first device (SightPlus) that has won critical acclaim, and which has demonstrated clinical excellence, we plan to develop a platform for home-based sight loss management that transforms eye health care and delivers value for patients, clinicians and health care providers.